---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-051051"
form_type: "8-K"
ticker: "CTNM"
cik: "0001855175"
company_name: "Contineum Therapeutics, Inc."
filed_at: "2026-07-30T20:08:07+00:00"
generated_at: "2026-07-30T20:09:27.810367+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Contineum Q2 net loss $15.2M; cash $236.6M; workforce reduction includes CSO departure

## Summary
- Net loss of $15.2M vs $16.0M in Q2 2025; R&D expense $12.7M (-10% YoY); G&A $4.7M (+23% YoY).
- Cash, equivalents and marketable securities $236.6M; runway projected through mid-2029.
- Workforce reduction in research team; CSO Daniel Lorrain, Ph.D. departing.
- PROPEL-IPF Phase 2 trial of PIPE-791 ongoing with >55 sites in 8 countries; J&J completed enrollment in Phase 2 MDD trial of JNJ-5120/PIPE-307.
- Positive Phase 1b topline data for PIPE-791 in chronic pain; safety consistent with prior trials.

## SEC filing metadata
- accession: 0001628280-26-051051
- form_type: 8-K
- ticker: CTNM
- cik: 0001855175
- company_name: Contineum Therapeutics, Inc.
- filed_at: 2026-07-30T20:08:07+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855175/000162828026051051/0001628280-26-051051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855175/000162828026051051/ctnm-20260730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-051051
- JSON: https://secwatch.observer/filing/0001628280-26-051051.json
- Plain text: https://secwatch.observer/filing/0001628280-26-051051.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.